Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions
- PMID: 7779718
- PMCID: PMC2033819
- DOI: 10.1038/bjc.1995.240
Expression of fibronectin, fibronectin isoforms and integrin receptors in melanocytic lesions
Abstract
In vitro studies have demonstrated that fibronectin (FN) can deliver a mitogenic signal to quiescent human melanoma cells and that the alpha 5/beta 1-integrin receptor mediates this stimulus. In view of this finding we have analysed the in vivo expression of FN, and of ED-A and ED-B FN isoforms, in benign and malignant lesions of melanocyte origin. In the same specimens the expression of fibronectin integrin receptors was evaluated. The results demonstrate that, while detection of FN does not correlate with transformation and tumour progression, the expression of the two isoforms is associated with transformation and that only the ED-A variant is found in metastases. Integrin phenotyping disclosed that alpha 3/beta 1 expression is associated with tumour progression, alpha v/beta 3 is a marker of transformation, alpha 4 is rarely expressed and alpha 5 is expressed by about 50% and 30% of the primary and metastatic lesions respectively. Taken together, the results of this study demonstrate that transformation and tumour progression of the melanocyte lineage are associated with modulation of expression of FN isoforms and FN integrin receptors. Furthermore, the expression of alpha 5-integrin in a considerable percentage of primary and metastatic lesions indicates that FN may deliver a proliferative stimulus to melanoma cells in vivo.
Similar articles
-
Emergence of alpha 5 beta 1 fibronectin- and alpha v beta 3 vitronectin-receptor expression in melanocytic tumour progression.Histopathology. 1994 Mar;24(3):249-56. doi: 10.1111/j.1365-2559.1994.tb00517.x. Histopathology. 1994. PMID: 7515372
-
Alpha v-integrins in human melanoma: gain of alpha v beta 3 and loss of alpha v beta 5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice.Int J Cancer. 1995 May 16;61(4):491-6. doi: 10.1002/ijc.2910610411. Int J Cancer. 1995. PMID: 7538977
-
Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.Cancer Res. 1989 Sep 15;49(18):5091-6. Cancer Res. 1989. PMID: 2548711
-
Immune reactions in benign and malignant melanocytic lesions: lessons for immunotherapy.Pigment Cell Melanoma Res. 2011 Apr;24(2):334-44. doi: 10.1111/j.1755-148X.2010.00799.x. Epub 2010 Nov 19. Pigment Cell Melanoma Res. 2011. PMID: 21029398 Review.
-
Cell adhesion receptor expression during melanoma progression and metastasis.Cancer Metastasis Rev. 1991 Jun;10(2):115-28. doi: 10.1007/BF00049409. Cancer Metastasis Rev. 1991. PMID: 1873852 Review.
Cited by
-
Survivin enhances motility of melanoma cells by supporting Akt activation and {alpha}5 integrin upregulation.Cancer Res. 2010 Oct 15;70(20):7927-37. doi: 10.1158/0008-5472.CAN-10-0194. Epub 2010 Aug 31. Cancer Res. 2010. PMID: 20807805 Free PMC article.
-
Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEA.Br J Cancer. 1997;76(6):777-83. doi: 10.1038/bjc.1997.461. Br J Cancer. 1997. PMID: 9310245 Free PMC article.
-
Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma.J Invest Dermatol. 2010 Aug;130(8):1971-87. doi: 10.1038/jid.2010.149. Epub 2010 Jun 17. J Invest Dermatol. 2010. PMID: 20555347 Free PMC article.
-
Detection of altered adhesion molecule expression in experimental tumors by a radiolabeled monoclonal antibody.Jpn J Cancer Res. 1997 Dec;88(12):1171-80. doi: 10.1111/j.1349-7006.1997.tb00346.x. Jpn J Cancer Res. 1997. PMID: 9473735 Free PMC article.
-
EDB Fibronectin-Specific SPECT Probe 99mTc-HYNIC-ZD2 for Breast Cancer Detection.ACS Omega. 2017 Jun 30;2(6):2459-2468. doi: 10.1021/acsomega.7b00226. Epub 2017 Jun 2. ACS Omega. 2017. PMID: 30023665 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
